Currency In USD
| Previous Close | 2.82 |
| Open | 2.83 |
| Day High | 3.06 |
| Day Low | 2.83 |
| 52-Week High | 5.15 |
| 52-Week Low | 2.44 |
| Volume | 290,281 |
| Average Volume | 533,321 |
| Market Cap | 277.52M |
| PE | -2.35 |
| EPS | -1.3 |
| Moving Average 50 Days | 3.35 |
| Moving Average 200 Days | 3.71 |
| Change | 0.23 |
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
GlobeNewswire Inc.
Mar 10, 2026 11:31 AM GMT
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
Mar 09, 2026 9:16 PM GMT
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a full